13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000310158
Total reported value
$526.4M
$526.4M
13 檔
40.9%
According to the latest 13F quarterly dataset, Merck & Co., Inc. managed an equity portfolio of $526.4M at the end of Q3 2025, spanning 13 distinct U.S. exchange-listed positions.
In Q3 2025, Merck & Co., Inc. displayed an active expansion posture, initiating 1 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PSNL | Personalis Inc | Stock-Other | 40.16% | +10.15% | — | |
| 2 | MRNA | Moderna Inc | Stock-Healthcare | 26.15% | -2.85% | — | |
| 3 | KYMR | Kymera Therapeutics Inc | Stock-Other | 19.17% | -1.58% | — | |
| 4 | ALEC | Alector Inc | Stock-Other | 4.60% | -0.83% | — | |
| 5 | ✓ | Stock-Other | 4.43% | -6.28% | EXIT | ||
| 6 | EVAXUSD | Evaxion Biotech A/s | Stock-Other | 2.00% | -1.29% | EXIT | |
| 7 | STRO | Sutro Biopharma, Inc. | Stock-Other | 1.04% | -1.94% | EXIT | |
| 8 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.88% | -0.19% | — | |
| 9 | ✓ | Lava Therapeutics NV | Stock-Other | 0.79% | — | — | |
| 10 | ✓ | Xilio Therapeutics Inc | Stock-Other | 0.55% | — | — | |
| 11 | CARM | Carisma Therapeutics Inc | Stock-Other | 0.18% | -0.01% | EXIT | |
| 12 | NEUP | Neuphoria Therapeutics Inc | Stock-Other | 0.05% | — | — | |
| 13 | HURA | Tuhura Biosciences Inc | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PSNL | Personalis Inc | +10.2% | — | Unchanged |
| 2 | KYMR | Kymera Therapeutics Inc | +6.3% | — | Unchanged |
| 3 | ALEC | Alector Inc | +2% | — | Unchanged |
| 4 | EVAXUSD | Evaxion Biotech A/s | +0.6% | — | Unchanged |
| 5 | VRDN | Viridian Therapeutics Inc | +0.1% | — | Unchanged |
| 6 | NEUP | Neuphoria Therapeutics Inc | 0% | — | Unchanged |
| 7 | STRO | Sutro Biopharma, Inc. | 0% | — | Unchanged |
| 8 | ✓ | Lava Therapeutics NV | -0.1% | — | Unchanged |
| 9 | ✓ | Xilio Therapeutics Inc | -0.1% | — | Unchanged |
| 10 | CARM | Carisma Therapeutics Inc | -0.1% | — | Unchanged |
| 11 | ✓ | -5.1% | — | Unchanged | |
| 12 | MRNA | Moderna Inc | -13.7% | — | Unchanged |
| 13 | HURA | Tuhura Biosciences Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Merck & Co., Inc. reported a total U.S. public equity portfolio value of $526.4M across 13 disclosed positions in Q3 2025.
During Q3 2025, Merck & Co., Inc.'s top holdings by market value included PSNL (40.2%)、MRNA (26.1%)、KYMR (19.2%). The largest single position, PSNL, represented 40.2% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PSNL, MRNA, KYMR) accounted for 40.9% of total reported equity market value during Q3 2025.
Top New Position Initiated
HURA
市值: $34.6K
In Q3 2025, Merck & Co., Inc. made 1 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.